 |
|
|
|
|
|
|
|
|
|
 |
|
| |
|
 |
BioValve Technologies, Inc. -- a speciality drug delivery company
BioValve Technologies Inc. is a specialty drug delivery company that is developing novel disposable pharmaceutical delivery systems that increase patient compliance and comfort. BioValve has two lead products, the Mini-Ject, a single-use disposable needle-less injector, and the e-Patch, a 24-hour patch-based pump for the subcutaneous delivery of pharmaceutical agents. In addition to providing superior delivery, these devices have the capability to extend the patent life of existing pharmaceuticals and thereby to offer a wide array of partnering possibilities. BioValve currently has multiple pharmaceutical collaborations in place and is actively developing several of its product-device combinations through FDA approval.
|
| |
| ^ back to top |
| |
| |
 |
HEALTHvision Inc. -- a leading Internet-based healthcare solutions provider
Healthvision creates Connected Healthcare Communities by helping market leaders quickly and cost-effectively plan for and deliver patient-centric information via shared information exchanges. Healthvision's capabilities cover the spectrum of needs ranging from a suite of strategic consulting services to web-based infrastructure and applications -- all designed to enhance decision making and effectiveness. The Healthvision e-Health Interoperability Platform and applications improve access to clinical information and enhance coordination and collaboration of care.
The company's Web-based infrastructure, e-healthSOURCE, is the most widely used in the industry, hosting more than 7.5 million unique patient records. Additionally, more than 350 healthcare organizations use the company's solutions to make health care easier for their key audiences - a number that represents more than 23,000 clinicians (including 11,000 physicians), thousands of patients and millions of consumers. A privately held company, based in Irving, Texas, Healthvision was formed in July 1999.
|
| |
| ^ back to top |
| |
| |
 |
RenaMed Biologics -- cellular therapies for inflammatory disease states
RenaMed Biologics is a clinical stage cellular therapy company dedicated to the design, development, and commercialization of human cell replacement systems for patients suffering from severe inflammatory disease states. The company has designed and validated its first application, the Renal Assist Device (RAD) for acute renal failure. The RAD is a novel extracorporeal device that along with standard Continuous Veno Venous Hemofiltration (CVVH) will be used to treat acute renal failure in the intensive care unit (ICU). RenaMed is currently developing this product in a multi-site Phase II clinical trial. Seaflower co-founded RenaMed in 1995 with Dr. David Humes, M.D. of the University of Michigan Medical Center.
|
| |
| ^ back to top |
| |
| |
 |
Serenex, Inc. -- proteomics-based drug discovery and development
Serenex is a proteomics-based drug discovery company. Its mission is to develop proprietary human therapeutics that have improved likelihoods of clinical and economic success. Serenex's proprietary technologies enable us to understand complex compound - multi-target interactions. It uses these technologies to discover novel compounds of interest and to rapidly move these compounds through our discovery pipeline. To date, Serenex has lead compounds and pre-clinical programs in oncology and inflammation related diseases scheduled to enter clinical trials in early 2006.
Using our proprietary technologies Serenex profiles compounds and libraries, in high throughput, against thousands of important target proteins simultaneously. This approach provides an order of magnitude more compound - target information than is otherwise available and by providing better starting points, it increases the likelihood that discovery phase programs will be successful. The company's technology improves drug discovery across every stage of the process; from targeted library screening to mechanism of action determination and toxicity profiling to lead optimization.
Since 2001, Serenex has worked with leading biotechnology and pharmaceutical companies improving their drug discovery programs in return for revenues and milestone payments. These companies include Chiron Corporation, Johnson & Johnson, Pfizer, Roche, Aventis and GlaxoSmithKline.
|
| |
| ^ back to top |
| |
| |
 |
Sopherion Therapeutics, Inc. -- oncology-focused specialty biopharmaceuticals
Sopherion is a specialty biopharmaceutical company focused on developing and marketing novel anti-cancer therapies for patients suffering with advanced cancer, including metastatic disease. Sopherion's lead product is Myocet®, a liposome-encapsulated doxorubicin-citrate complex. Myocet® has been approved by the European and Canadian regulatory agencies for first line therapy in combination with cyclophosphamide for patients with metastatic breast cancer. Zeneus Pharma currently markets Myocet® in the United Kingdom, Austria, France, Germany, Ireland, Italy, Portugal and Spain.
Sopherion intends to launch Myocet® in Canada in Q3 2005. In the United States, Sopherion will manage the regulatory process, and pending FDA approval, be responsible for the marketing and sales of this therapy. To date, several large clinical trials of Myocet® have been completed in the United States and Europe. Extensive clinical studies of Myocet® in women with breast cancer have shown that the severe toxicity of doxorubicin to the heart and the cells that line the gastrointestinal tract can be significantly moderated while the efficacy of the drug is maintained.
Sopherion also leverages its proprietary screening platform to design and identify new therapies. The platform is built on a next generation peptide display technology called Minicell Peptide Display™ (MiniPep Display or MPD) that is able to circumvent limitations inherent with conventional Phage or Bacterial display technologies. MPD uses minicells -- small vesicles produced by bacteria that possess a critical mutation and lack chromosomal DNA.
|
| |
| ^ back to top |
| |
| |
 |
Targanta Therapeutics, Inc. -- developing novel antibacterials
Targanta (formerly PhageTech) is a biopharmaceutical company developing small-molecule antibacterial agents aiming at the disruption of the DNA replication and transcription machinery through the targets of bacteriophages ("phages"), viruses that attack bacteria. Targanta's approach effectively mimics strategies devised through four billion years of evolutionary pressure with regards to the selection of druggable bacterial targets and circumvents the demonstrated limitations of sequencing bacterial genomes as a way to identify novel antibacterial targets and new classes of antibacterials. In addition, Targanta is developing novel antibacterial pro-drugs for the treatment and prevention of osteomyelitis (bacterial infections of the bone). No currently marketed antibiotics have an FDA-approved osteomyelitis indication, leaving a large and untapped market for the prevention and/or treatment of this affliction.
|
| |
| ^ back to top |
| |
| |
 |
Veritas Medicine, Inc. -- web and database solutions for the patient recruitment
Veritas Medicine is a leading provider of clinical trial assessment and recruitment services. The company's services are two to ten times more cost-efficient than traditional media recruitment campaigns. The company's centerpiece is a comprehensive clinical trials database that allows patients to be matched to clinical trials based on information submitted confidentially. The clinical trial matching tool is supplemented with original, high-quality information about current and investigational treatments developed by physicians from leading academic medical centers. This information assists patients and health professionals in making informed decisions regarding their treatment options. Veritas's technology enabled solutions have served over 300 trials for more than sixty trial sponsors, including 12 of the top 20 pharmaceutical companies.
|
| |
| ^ back to top |
| |
| |
 |
Zelos Therapeutics, Inc. -- PTH therapies for osteoporosis and other diseases
Zelos Therapeutics, Inc. is a biopharmaceutical development company with exclusive worldwide licenses to a broad family of small parathyroid hormone (PTH) analogues with therapeutic applications for osteoporosis, psoriasis and stem cell engraftment. Animal and initial human studies indicate that Zelos' lead PTH analogue, Ostabolin-C, is much more potent and safer than competing PTH products (Forteo/Lilly; Preos/NPS). Due to enhanced stability, Zelos's proprietary PTH analogues also appear to offer superior potential for pulmonary formulation and oral delivery. Zelos maintains administrative offices in Waltham, Massachusetts, and research facilities in Ottawa, Ontario.
|
| |
| ^ back to top |
| |
| |
| |
|
 |
ViaCell, Inc. (IPO) -- Nasdaq: VIAC
ViaCell Inc. is a clinical-stage biotechnology company dedicated to enabling the widespread application of human cells as medicine. The Company is developing a pipeline of proprietary product candidates intended to address cancer, infertility, and cardiac diseases. ViaCell's proprietary technologies include Selective Amplification technology, which the Company believes will enable the development of high- definition stem cell products based on the isolation, purification and significant expansion of targeted stem cell populations. ViaCell is using these assets to develop a cord blood-derived stem cell therapeutic, CB001, the Company's lead stem cell therapy product candidate, which is currently in a Phase I clinical trial. ViaCell also markets its Viacord Viacord umbilical cord blood preservation product, which is used primarily for pediatric bone marrow transplants. Seaflower was the lead investor in ViaCell's first venture capital financing round. ViaCell completed an IPO in January 2005. |
| |
| ^ back to top |
| |
| |
 |
GelTex Pharmaceuticals Inc. (IPO/ACQUIRED) -- Nasdaq:GLTX
GelTex was founded to develop and commercialize a new class of non-absorbable pharmaceuticals for the selective elimination of substances resulting from certain disease states or whose elimination will have a beneficial medical effect. The company's lead product, Renagel® brand sevelamer hydrochloride, was granted marketing approval by the FDA in 1998 for the reduction of serum phosphorus in hemodialysis patients. GelTex's second product, Welchol brand colesevelam hydrochloride, was granted marketing approval by the FDA in 2000 for the treatment of hypercholesterolemia, a condition characterized by undesirably high cholesterol levels. The company is also developing treatments for non-systemic infections, oral mucositis, cancer, and iron overload.
Seaflower's founder was an investor in GelTex's initial round of seed funding. GelTex completed an IPO in November 1995, and was subsequently acquired by Genzyme Corp. for $1 billion. |
| |
| ^ back to top |
| |
| |
 |
EPIX Medical, Inc. (IPO) -- Nasdaq:EPIX
EPIX Medical is a specialty pharmaceutical company founded to develop targeted contrast agents to transform the diagnosis and clinical management of cardiovascular disease and to improve the capability of magnetic resonance imaging (MRI) as a diagnostic tool for a variety of diseases. The Company's principal product under development, MS-325, is an injectable intravascular MRI contrast agent designed for multiple vascular imaging applications, including peripheral vascular disease and coronary artery disease. Seaflower's founder was an investor in one of EPIX Medical's early financing rounds. EPIX completed an IPO in March 1995. |
| |
| ^ back to top |
| |
| |
 |
Alpha-Beta Technologies, Inc. (IPO) -- Nasdaq:ABTI
Alpha-Beta was founded to research and develop new classes of carbohydrate and antifungal products. The company's lead product was Betafectin for inflammatory bowel disease (IBD) and the prevention of serious post-operative infections in non-colorectal gastrointestinal surgery patients.
Seaflower's founder was an investor in Alpha-Beta's initial seed round of funding. Alpha-Beta completed an IPO in 1992. |
| |
| ^ back to top |
| |
| |
 |
endoVia Medical, Inc. (ACQUIRED)
endoVia Medical is a medical technology company developing second generation computer-assisted surgical devices for minimally invasive surgery (MIS) and interventional medicine. endoVia has developed a robotic guidance system for controlling laparoscopic and catheter-based instruments that will open large, new patient populations to less invasive procedures. endoVia is developing two proprietary product platforms: the Laprotek™ System for MIS; and the catheter-based Endoluminal Surgery System for interventional medicine. Seaflower was the lead investor in endoVia's initial venture capital financing round. endoVia was acquired in 2005 by Hansen Medical. |
| |
| ^ back to top |
| |
| |
 |
eMed Technologies (ACQUIRED)
eMed is a provider of Picture Archiving and Communications Systems (PACS) and web-based medical imaging radiology solutions. eMed's product suite includes PACS components to capture, compress, distribute, display and store medical images, RIS and RIS integration, and web-enabled image and report distribution for clinicians. Today, more than 7,800 radiologists and 2,000 hospitals and imaging centers use eMed image management, teleradiology and web solutions to manage images and grow their business. Seaflower was a the lead investor in eMed's initial venture capital financing round. eMed Technologies was acquired for $47 million in October 2004 by Cedara Software Corp. |
| |
| ^ back to top |
| |
| |
 |
MetaWorks, Inc. -- evidence-based medical information services
MetaWorks Inc. has gained a reputation as one of the healthcare industry's most expert and reliable sources for Evidence-Based Medical Information and technology. MetaWorks is a leading provider of systematic reviews, meta-analyses and other evidence-based-information services for more than 50 companies in the pharmaceutical, biotechnology, medical device, hospital, and health care provider industries. In 1997, MetaWorks was awarded a designation as one of 12 Evidence-Based Practice Centers (EPCs) by the U.S. Department of Health's Agency for Health Care Policy and Research (AHCPR), now the Agency for Health Care Research and Quality (AHRQ). MetaWorks is an industry innovator: We developed MetaHub™ (our unprecedented, proprietary clinical-trials database) and EvidenceHub.com (our online data-review software) to provide state-of-the-art electronic evidence-based medical information.
Our work has been published in numerous peer-reviewed journals and has resulted in successful submissions to regulatory authorities worldwide.
With a highly trained scientific staff, innovative services and technologies, a steadfast commitment to scientific excellence and customer service, MetaWorks is uniquely qualified to deliver the fast, clear, accurate answers the healthcare industry needs most.
|
| |
| ^ back to top |
| |
| |
U.S. CareLink, Inc. (ACQUIRED)
U.S. CareLink was an Internet-based clinical information company founded to develop a Web-based ambulatory care management system that allows physicians, patients and family members to share information online through easy-to-use Web technology. Seaflower was the lead investor in U.S. CareLink's first venture capital financing. U.S. CareLink was acquired in 1999 by HEALTHvision. |
| |
| ^ back to top |
| |
| |
 |
Synthon Chiragenics Corp. (ACQUIRED)
Synthon was the world-leader in carbohydrate-based chiral technology for pharmaceuticals. Synthon is the first and only company to unlock the rich source of chirality contained in naturally occurring carbohydrates. The company uses its proprietary technology to economically construct the most challenging chiral molecules, which serve as cores for drugs being developed in the fastest-growing therapeutic areas: anti-virals, antibiotics and anti-cancer. Seaflower co-founded Synthon with Prof. Rawle Hollingsworth, Ph.D., of Michigan State University, and served as the lead investor in Synthon's initial seed financing rounds. Synthon was acquired by Avecia in 2003. |
| |
| ^ back to top |
| |
| |
|
|
 |
|
|
|
|
|
|
|
 |
|
|
|
